论文部分内容阅读
免疫性血小板减少性紫癜(ITP)是一种获得性免疫性疾病。该疾病由抗血小板抗体介导,以血小板破坏增多和血小板生成减少为特征。目前的临床研究在评估患者时采用的定义和临床标准有广泛差异,从而导致研究结果的不均衡,结论不可靠。特别是对一些新药疗效进行评估的临床研究,更突显ITP实行统一标准的必要性。近年来由于对免疫介导的血小板破坏途径和血小板生成适宜条件重要性等方面的认识不深,促进了新药的研发。现阐述ITP的发病机制,有关定义和疗效判断标准,一些新药的药理学、耐受性、药物毒性及疗效等方面的进展。
Immune thrombocytopenic purpura (ITP) is an acquired immune disease. The disease is mediated by anti-platelet antibodies, characterized by increased platelet destruction and reduced platelet production. Current clinical studies have widely divergent definitions and clinical criteria used in assessing patients, leading to an imbalance of findings and unreliable conclusions. In particular, clinical studies evaluating the efficacy of some new drugs have highlighted the need for a uniform standard for ITP. In recent years, due to the lack of understanding of the immune-mediated pathways of platelet destruction and the importance of appropriate conditions for platelet production, research and development of new drugs have been promoted. Now ITP pathogenesis, the definition of the criteria and efficacy criteria, the pharmacology of some new drugs, tolerance, toxicity and efficacy of drug progress.